Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.65
(3.78%)
TWD 35.65
(3.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.47 Billion TWD | 26.04% |
| 2022 | 1.17 Billion TWD | -1.28% |
| 2021 | 1.18 Billion TWD | 12.61% |
| 2020 | 1.05 Billion TWD | -4.05% |
| 2019 | 1.1 Billion TWD | 12.88% |
| 2018 | 974.63 Million TWD | -18.17% |
| 2017 | 1.19 Billion TWD | 13.54% |
| 2016 | 1.04 Billion TWD | -0.2% |
| 2015 | 1.05 Billion TWD | -20.02% |
| 2014 | 1.31 Billion TWD | 11.27% |
| 2013 | 1.18 Billion TWD | -20.62% |
| 2012 | 1.48 Billion TWD | 15.26% |
| 2011 | 1.29 Billion TWD | 23.14% |
| 2010 | 1.04 Billion TWD | 17.63% |
| 2009 | 891.18 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.37 Billion TWD | -7.16% |
| 2024 Q2 | 1.36 Billion TWD | -0.9% |
| 2023 Q4 | 1.47 Billion TWD | 3.36% |
| 2023 Q1 | 1.12 Billion TWD | -4.18% |
| 2023 FY | 1.47 Billion TWD | 26.04% |
| 2023 Q2 | 1.33 Billion TWD | 18.77% |
| 2023 Q3 | 1.43 Billion TWD | 7.15% |
| 2022 Q3 | 1.13 Billion TWD | -8.73% |
| 2022 FY | 1.17 Billion TWD | -1.28% |
| 2022 Q4 | 1.17 Billion TWD | 3.55% |
| 2022 Q2 | 1.24 Billion TWD | 11.5% |
| 2022 Q1 | 1.11 Billion TWD | -6.31% |
| 2021 Q2 | 1.15 Billion TWD | 16.9% |
| 2021 Q3 | 1.13 Billion TWD | -1.59% |
| 2021 FY | 1.18 Billion TWD | 12.61% |
| 2021 Q4 | 1.18 Billion TWD | 4.62% |
| 2021 Q1 | 987.64 Million TWD | -6.44% |
| 2020 Q4 | 1.05 Billion TWD | -2.63% |
| 2020 Q2 | 1.38 Billion TWD | 16.99% |
| 2020 FY | 1.05 Billion TWD | -4.05% |
| 2020 Q3 | 1.08 Billion TWD | -21.63% |
| 2020 Q1 | 1.18 Billion TWD | 7.49% |
| 2019 Q1 | 926.87 Million TWD | -4.9% |
| 2019 Q4 | 1.1 Billion TWD | 10.22% |
| 2019 FY | 1.1 Billion TWD | 12.88% |
| 2019 Q3 | 998.12 Million TWD | 4.33% |
| 2019 Q2 | 956.71 Million TWD | 3.22% |
| 2018 Q2 | 1.17 Billion TWD | 7.32% |
| 2018 Q3 | 1.09 Billion TWD | -6.66% |
| 2018 FY | 974.63 Million TWD | -18.17% |
| 2018 Q1 | 1.09 Billion TWD | -8.1% |
| 2018 Q4 | 974.63 Million TWD | -11.11% |
| 2017 Q3 | 1.17 Billion TWD | -5.28% |
| 2017 Q4 | 1.19 Billion TWD | 1.1% |
| 2017 FY | 1.19 Billion TWD | 13.54% |
| 2017 Q1 | 982.1 Million TWD | -6.38% |
| 2017 Q2 | 1.24 Billion TWD | 26.65% |
| 2016 Q4 | 1.04 Billion TWD | 0.32% |
| 2016 FY | 1.04 Billion TWD | -0.2% |
| 2016 Q3 | 1.04 Billion TWD | 0.3% |
| 2016 Q2 | 1.04 Billion TWD | 7.07% |
| 2016 Q1 | 973.62 Million TWD | -7.37% |
| 2015 Q3 | 1.19 Billion TWD | -15.63% |
| 2015 Q4 | 1.05 Billion TWD | -12.03% |
| 2015 FY | 1.05 Billion TWD | -20.02% |
| 2015 Q1 | 1.34 Billion TWD | 2.14% |
| 2015 Q2 | 1.41 Billion TWD | 5.5% |
| 2014 Q2 | 1.17 Billion TWD | 0.5% |
| 2014 Q1 | 1.16 Billion TWD | -1.09% |
| 2014 Q4 | 1.31 Billion TWD | 9.99% |
| 2014 Q3 | 1.19 Billion TWD | 1.77% |
| 2014 FY | 1.31 Billion TWD | 11.27% |
| 2013 Q4 | 1.18 Billion TWD | -4.11% |
| 2013 Q1 | 1.11 Billion TWD | -24.87% |
| 2013 Q2 | 1.24 Billion TWD | 11.58% |
| 2013 Q3 | 1.23 Billion TWD | -1.25% |
| 2013 FY | 1.18 Billion TWD | -20.62% |
| 2012 FY | 1.48 Billion TWD | 15.26% |
| 2012 Q1 | 1.37 Billion TWD | 6.47% |
| 2012 Q4 | 1.48 Billion TWD | -0.87% |
| 2012 Q3 | 1.5 Billion TWD | 3.32% |
| 2012 Q2 | 1.45 Billion TWD | 5.69% |
| 2011 Q3 | 1.19 Billion TWD | 9.49% |
| 2011 FY | 1.29 Billion TWD | 23.14% |
| 2011 Q1 | 1.11 Billion TWD | 6.12% |
| 2011 Q2 | 1.09 Billion TWD | -1.94% |
| 2011 Q4 | 1.29 Billion TWD | 8.08% |
| 2010 Q4 | 1.04 Billion TWD | 0.0% |
| 2010 FY | 1.04 Billion TWD | 17.63% |
| 2009 FY | 891.18 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Maxigen Biotech Inc. | 131.88 Million TWD | -1021.499% |
| SciVision Biotech Inc. | 533.66 Million TWD | -177.153% |
| Bionime Corporation | 3.3 Billion TWD | 55.28% |
| Pegavision Corporation | 3.87 Billion TWD | 61.863% |
| Visco Vision Inc. | 1.74 Billion TWD | 15.071% |